Chester Kao

599 total citations
19 papers, 330 citations indexed

About

Chester Kao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Chester Kao has authored 19 papers receiving a total of 330 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Chester Kao's work include Cancer Immunotherapy and Biomarkers (12 papers), Renal cell carcinoma treatment (6 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Chester Kao is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Renal cell carcinoma treatment (6 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Chester Kao collaborates with scholars based in United States, Switzerland and India. Chester Kao's co-authors include Tian Zhang, Andrew J. Armstrong, Michael R. Harrison, Daniel J. George, Eric R. Powers, Jeremy Chang, R. Stephanie Huang, Fan Wang, Georgia Sofia Karachaliou and Christopher Hoimes and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Hematology & Oncology.

In The Last Decade

Chester Kao

19 papers receiving 329 citations

Peers

Chester Kao

ONCOL

PRM

IMMUN

Xiuju Du China

M. D’Arcangelo Italy

Danmei Pang China

Peter Schirmacher Germany

Chukwuemeka Ikpeazu United States

Nobuhiko Nishijima Japan

Davide Bosso Italy

Sebastian Michels Germany

Nishi Kothari United States

Xiaonan Shi China

Xiuju Du China

Chester Kao

159 ×1.0

ONCOL

158 ×1.0

PRM

128 ×1.2

124 ×1.1

46 ×1.1

IMMUN

Citations per year, relative to Chester Kao Chester Kao (= 1×) peers Xiuju Du

Countries citing papers authored by Chester Kao

Since Specialization

Citations

This map shows the geographic impact of Chester Kao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chester Kao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chester Kao more than expected).

Fields of papers citing papers by Chester Kao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chester Kao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chester Kao. The network helps show where Chester Kao may publish in the future.

Co-authorship network of co-authors of Chester Kao

This figure shows the co-authorship network connecting the top 25 collaborators of Chester Kao. A scholar is included among the top collaborators of Chester Kao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chester Kao. Chester Kao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Alden, Stephanie, Chester Kao, Daniel Shu, et al.. (2023). Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma. Cancer Research Communications. 3(7). 1312–1317. 21 indexed citations

Alden, Stephanie, Chester Kao, Daniel Shu, et al.. (2023). Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade.. Journal of Clinical Oncology. 41(16_suppl). 4091–4091. 2 indexed citations

Balaji, Aanika, Stephanie Alden, Howard Li, et al.. (2023). Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population.. Journal of Clinical Oncology. 41(16_suppl). 2662–2662. 2 indexed citations

Brown, Landon C., Kunal Desai, Wei Wei, et al.. (2021). Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. Journal for ImmunoTherapy of Cancer. 9(9). e003281–e003281. 13 indexed citations

Tucker, Matthew D., Landon C. Brown, Yu‐Wei Chen, et al.. (2021). Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomarker Research. 9(1). 80–80. 28 indexed citations

Desai, Kunal, Landon C. Brown, Wei Wei, et al.. (2021). A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab. Targeted Oncology. 16(5). 633–642. 12 indexed citations

Kao, Chester, Eric R. Powers, Yuan Wu, et al.. (2021). Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Clinical Lung Cancer. 22(6). 500–509. 23 indexed citations

Brown, Landon C., Matthew D. Tucker, Ramy Sedhom, et al.. (2021). LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. Journal for ImmunoTherapy of Cancer. 9(3). e001792–e001792. 73 indexed citations

Tucker, Matthew D., Landon C. Brown, Chester Kao, et al.. (2021). Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 39(15_suppl). 4563–4563. 2 indexed citations

10.

Powers, Eric R., Georgia Sofia Karachaliou, Chester Kao, et al.. (2020). Novel therapies are changing treatment paradigms in metastatic prostate cancer. Journal of Hematology & Oncology. 13(1). 144–144. 82 indexed citations

11.

Brown, Landon C., Ramy Sedhom, Eric Schwartz, et al.. (2020). Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.. Journal of Clinical Oncology. 38(15_suppl). 3007–3007. 5 indexed citations

12.

Ortel, Thomas L., Andrew Morgan, Chester Kao, et al.. (2020). COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy. Blood. 136(Supplement 1). 23–24. 1 indexed citations

13.

Kao, Chester, Daniel J. George, & Tian Zhang. (2020). An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC). The Oncologist. 26(3). e508–e511. 3 indexed citations

14.

Kao, Chester, Eric R. Powers, Michael Datto, et al.. (2020). Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors.. Journal of Clinical Oncology. 38(5_suppl). 80–80. 6 indexed citations

15.

Brown, Landon C., Kunal Desai, Chester Kao, et al.. (2020). A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab.. Journal of Clinical Oncology. 38(6_suppl). 637–637. 3 indexed citations

16.

Desai, Kunal, Landon C. Brown, Wei Wei, et al.. (2020). Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab.. Journal of Clinical Oncology. 38(6_suppl). 648–648. 1 indexed citations

17.

Kao, Chester, Megan McNamara, Neil L. Spector, et al.. (2019). A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder. Clinical Genitourinary Cancer. 17(3). e672–e677. 4 indexed citations

18.

Zhu, Jason, Matthew D. Tucker, Chester Kao, et al.. (2019). Immune checkpoint inhibitor response in tumors with LRP1B variants.. Journal of Clinical Oncology. 37(15_suppl). e14291–e14291. 2 indexed citations

19.

Wang, Fan, Jeremy Chang, Chester Kao, & R. Stephanie Huang. (2016). High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in Ovarian Cancer Both In Vivo and In Vitro. Molecular Cancer Therapeutics. 15(5). 1123–1131. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact